Utility of Neuropathy Screening for Wild-Type Transthyretin Amyloidosis Patients.
Angela Russell, Christopher Hahn, Sameer Chhibber...
https://pubmed.ncbi.nlm.nih.gov/33342448Actively Recruiting
Phase Not Applicable
Age: 60Years +
All Genders
ID05950867
Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause: a Prospective Monocentric Study (CAP-TTR)
Led by Universitair Ziekenhuis Brussel · Updated on 2025-07-22
150
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating whether chronic axonal length-dependent polyneuropathy (CAP) and/or small-fiber neuropathy (SFN) might be early signs of wild-type TTR cardiac amyloidosis (wtTTR-CA), a heart condition. The study aims to explore if recognizing these neuropathies can lead to faster diagnosis and better clinical outcomes for wtTTR-CA. This prospective monocentric study focuses on patients with polyneuropathy of unknown cause. Participants with CAP and/or SFN, who have already undergone nerve conduction studies (NCS), electromyography (EMG), and Sudoscan® testing, will be invited for a single combined neurology and cardiology visit. During this visit, they will undergo assessments including symptom evaluation using NTSS-6 and COMPASS31 questionnaires, physical examination scales (mPND, NIS), a Kansas City Cardiomyopathy Questionnaire (KCCQ), electrocardiogram (ECG), and echocardiography. Retrospective data from their medical records, including previous tests and lab results, will also be reviewed. During the study visit, participants will complete questionnaires on neuropathy and cardiac symptoms and receive heart and nerve function tests. Researchers will analyze the prevalence of wild-type cardiac amyloidosis in this group over 36 months. They will also monitor symptom severity, progression, and identify warning signs that could help neurologists recognize cardiac amyloidosis earlier. The total participation involves one study visit and retrospective data analysis without long-term follow-up visits.
CONDITIONS
Brief Title
Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause.
Who Can Participate
Age: 60Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Patients with chronic axonal length-dependent polyneuropathy (CAP) and/or small-fiber neuropathy (SFN) without well-defined cause
- Age 60 years or older
- Male and female gender
- Written informed consent
You will not qualify if you...
- Known cause of polyneuropathy
- Peripheral neuropathy types other than CAP or SFN
- Patients younger than 60 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Surveillance
Duration - Single day visit
Participants undergo one visit during which questionnaires about polyneuropathy and cardiological symptoms are completed, and diagnostic tests including electrocardiogram and echocardiography are performed to assess cardiac amyloidosis.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
UZ Brussel
Jette, Belgium Capital City, Belgium, 1090
Actively Recruiting
Loading map...
Research Team
V
Véronique Bissay, MD,Phd
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.
Felix Kleefeld, Elise Scherret, Fabian Knebel...
https://pubmed.ncbi.nlm.nih.gov/34994254Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type.
Aikaterini Papagianni, Sandra Ihne, Daniel Zeller...
https://pubmed.ncbi.nlm.nih.gov/34632904Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Fabio A Barroso, Teresa Coelho, Angela Dispenzieri...
https://pubmed.ncbi.nlm.nih.gov/35451899Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild-type cardiac amyloidosis.
Mounira Kharoubi, Fréderic Roche, Mélanie Bézard...
https://pubmed.ncbi.nlm.nih.gov/33354901Peripheral neuropathy symptoms in wild type transthyretin amyloidosis.
Fernanda Wajnsztajn Yungher, Arreum Kim, Amelia Boehme...
https://pubmed.ncbi.nlm.nih.gov/32627282Chronic idiopathic axonal polyneuropathy: a systematic review.
Panagiotis Zis, Ptolemaios Georgios Sarrigiannis, Dasappaiah Ganesh Rao...
https://pubmed.ncbi.nlm.nih.gov/26961897Axonal Sensorimotor Polyneuropathies.
Yuebing Li
https://pubmed.ncbi.nlm.nih.gov/28968367The Investigation of the Cardiovascular and Sudomotor Autonomic Nervous System-A Review.
Tjalf Ziemssen, Timo Siepmann
https://pubmed.ncbi.nlm.nih.gov/30809183Diagnosis of peripheral neuropathy.
Helmar C Lehmann, Gilbert Wunderlich, Gereon R Fink...
https://pubmed.ncbi.nlm.nih.gov/33324924